GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeNeuro SA (FRA:GEM) » Definitions » FCF Margin %

GeNeuro (FRA:GEM) FCF Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is GeNeuro FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. GeNeuro's Free Cash Flow for the six months ended in Dec. 2023 was €-5.44 Mil. GeNeuro's Revenue for the six months ended in Dec. 2023 was €0.00 Mil. Therefore, GeNeuro's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, GeNeuro's current FCF Yield % is -495.67%.

The historical rank and industry rank for GeNeuro's FCF Margin % or its related term are showing as below:


During the past 11 years, the highest FCF Margin % of GeNeuro was 463.73%. The lowest was -257.23%. And the median was -51.64%.

FRA:GEM's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -145.32
* Ranked among companies with meaningful FCF Margin % only.

GeNeuro FCF Margin % Historical Data

The historical data trend for GeNeuro's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeNeuro FCF Margin % Chart

GeNeuro Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

GeNeuro Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of GeNeuro's FCF Margin %

For the Biotechnology subindustry, GeNeuro's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GeNeuro's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GeNeuro's FCF Margin % distribution charts can be found below:

* The bar in red indicates where GeNeuro's FCF Margin % falls into.


GeNeuro FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

GeNeuro's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-10.172/0
= %

GeNeuro's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-5.44/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GeNeuro FCF Margin % Related Terms

Thank you for viewing the detailed overview of GeNeuro's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

GeNeuro Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeNeuro SA (FRA:GEM) » Definitions » FCF Margin %
Comparable Companies
XPAR:ALGEN XPAR:ALVIO XPAR:PHXM XPAR:ALDVI XPAR:ABNX XPAR:SIGHT XPAR:ALCOX XPAR:ALACT XPAR:POXEL XPAR:ALCLS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
GNROp:UK GNRO:France
Address
3 chemin du Pre-Fleur, Plan-les-Ouates, Geneva, CHE, 1228
Website
https://www.geneuro.com
GeNeuro SA is a clinical-stage biopharmaceutical company focused on understanding and stopping causal factors driving the progression of neurodegenerative and autoimmune diseases. The company's therapeutic candidate, temelimab, is a humanized monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family (W-ENV).